Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.

Vancouver, British Columbia – March 10, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has entered into a definitive share purchase agreement (the " SPA ") dated March 9, 2026 between the Company, CliniQuantum Ltd. (“ CliniQ ”) and the Selling Shareholders (as defined below) to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQ (the " CliniQ Shares "), a quantum technology company  in the field of quantum simulation and quantum based Monte Claro (the " Transaction "). CliniQ is developing a next-generation platform to transform clinical trials with the power of quantum computing. Its aim is to unlock insights hidden in massive, complex datasets to design smarter, faster, and more adaptive studies.   Transaction Overview